Abstract:Children and adolescents hospitalized with infectious and inflammatory conditions are at risk of neurological sequelae, presenting clinicians with the formidable task of identifying those at greatest risk of morbidity. Francoeur et al 1 present an approach this challenge through the lens of pediatric neurocritical care. In their secondary analysis of the pediatric Global Consortium Study of Neurologic Dysfunction in COVID-19 (GCS-NeuroCOVID), they observed that severe neurological manifestations were strikingly common in hospitalized children and adolescents (ie, from birth to <18 years) with acute SARS-CoV-2 infection and multisystem inflammatory syndrome in children (MIS-C), occurring in 18.0% and 24.8%, respectively. Acute encephalopathy accounted for most of the neurological sequelae in both conditions. The study demonstrated an association between severe neurological manifestations and new functional or neurocognitive morbidity, as measured by the Functional Status Scale and the Pediatric Cerebral Performance Category scale. This pivotal study applies a robust definition of severe neurological manifestations, determined by expert consensus, to a large international cohort of hospitalized young patients. The resulting analysis highlights the strengths and also some limitations of such datasets, underscoring the need to better understand risk factors for and downstream consequences of neurological sequelae in hospitalized children and adolescents. This report provides evidence that individuals younger than 18 years with preexisting neurological conditions are more likely to develop severe neurological manifestations of both acute SARS-CoV-2 infection and MIS-C. Overall severity of systemic illness may partially explain these findings, given that children with chronic neurological disorders are known to be at increased risk of severe COVID-19. 2 These analyses underscore a critical need for vigilant neurological monitoring in this vulnerable population. Underlying seizure disorders may be of particular significance in the GCS-NeuroCOVID cohort. In the case of acute SARS-CoV-2, seizures or status epilepticus constituted over 40% of severe neurological manifestations reported. In a previous large cohort study, children and adolescents with neurological sequelae of COVID-19 and MIS-C were more likely to have preexisting seizure disorders. 3 While the proportion of the GCS-NeuroCOVID cohort that had an underlying seizure disorder was not known, the study highlights a need for enhanced awareness of the risk of seizures and potential subsequent neurocognitive and functional impairment. Clinical, laboratory, and radiological observations from this study may reflect pathobiological mechanisms underlying neurological manifestations of acute infectious and inflammatory conditions such as SARS-CoV-2 and MIS-C. Lower platelet counts were seen in patients with severe neurological manifestations with both acute SARS-CoV-2 infection and MIS-C. This finding could represent a marker of overall disease severity, an interpretation that would align with a previously observed association between lower platelet count and mortality in adults with COVID-19. 4 Median observed platelet counts did not meet the threshold for thrombocytopenia, potentially indicating a more nuanced relationship between neurological manifestations and platelet number or possibly function. Immunomodulator and antiviral therapies (ie, corticosteroids, remdesivir, and intravenous immunoglobulin) were given in larger proportions to patients with acute neurological manifestations. One possible interpretation is that these therapies are given to children with greater overall disease severity. Alternatively, the presence of neurological complications might have influenced the decision to use these interventions. Taken together, these differences in platelet counts and immunomodulator therapies may implicate inflammatory mechanisms leading to neurological disease. A recent proteomic investigation identified evidence of endothelial and platelet activation in serum from patients with SARS-CoV-2–related inflammation. 5 This observed inflammatory signature might partially explain the neurovascular injuries seen in COVID-19. In the GCS-NeuroCOVID cohort, abnormal magnetic resonance imaging findings were more common in patients with acute SARS-CoV-2 with severe neurological manifestations than in those without. In pediatric sepsis, abnormal magnetic resonance imaging findings—predominately white matter signal changes and ischemia—are associated with mortality and new neurological disability. 6 Future descriptions of the specific patterns of abnormal imaging in the GCS-NeuroCOVID cohort could yield greater insight into mechanisms of acquired brain injury in children with SARS-CoV-2. Elucidating these mechanisms could lead to improved recognition of individ -Abstract Truncated-

Child with tuberculous meningitis and COVID-19 coinfection complicated by extensive cerebral sinus venous thrombosis

Cerebral vasculopathy and strokes in a child with COVID-19 antibodies: illustrative case

Severe neurological complications in a child with multisystem inflammatory syndrome in children after asymptomatic COVID-19

Children and young adults hospitalized for severe COVID-19 exhibit thrombotic coagulopathy

Thrombotic complications in children with Coronavirus disease 2019 and Multisystem Inflammatory Syndrome of Childhood

Thrombosis in Multisystem Inflammatory Syndrome Associated with COVID-19 in Children: Retrospective Cohort Study Analysis and Review of the Literature

Post-COVID-19 Multisystem Inflammatory Syndrome-Related Cerebral Infarction in a Pediatric Patient Managed with Decompressive Craniectomy

Case report: unprecedented case of infantile cerebral infarction following COVID-19 and favorable outcome

Left ventricular mural thrombi with multisystem thrombosis in patients with COVID-19 and myocardial injury: a case series

COVID-19 Associated Hemophagocytic Lymphohistiocytosis and Coagulopathy: Targeting the Duumvirate

Cerebral Venous Sinus Thrombosis (CVST) in a Young Female with COVID-19 Infection and Oral Contraceptive Pill Ingestion Double Hit? – A Case Report

Multisystem inflammatory syndrome in children with COVID-19 in a multitransfused patient

Three Cases of Pediatric Multisystem Inflammatory Syndrome Associated with COVID-19 Due to SARS-CoV-2

Severe Neurological Manifestations in Pediatric Patients with SARS-CoV-2 or MIS-C

Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C

Tuberculosis Meningitis in a 9-Month-Old Girl during the COVID-19 Pandemic

Concurrent Cerebral, Splenic, and Renal Infarction in a Patient With COVID-19 Infection

Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children

Are children with SARS‐CoV‐2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients

How we approach thrombosis risk in children with COVID‐19 infection and MIS‐C

Concurrent Pansinusitis and Orbital Cellulitis Complicated by Extensive Head and Neck Venous Thrombosis in an Unvaccinated Adolescent Patient with COVID-19: A Case Report